Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas
- PMID: 21411445
- DOI: 10.1158/1078-0432.CCR-10-1688
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas
Abstract
Purpose: Ovarian clear cell carcinomas (OCCC) are a drug-resistant and aggressive type of epithelial ovarian cancer. We analyzed the molecular genetic profiles of OCCCs to determine whether distinct genomic subgroups of OCCCs exist.
Experimental design: Fifty pure primary OCCCs were subjected to high-resolution microarray-based comparative genomic hybridization (aCGH). Unsupervised hierarchical clustering using Ward's linkage analysis was performed to identify genomic subgroups of OCCCs. Survival analysis was performed using Kaplan-Meier method and log-rank test. Cox-regression analysis was used to identify independent predictors of outcome. Differentially amplified regions between genomic subgroups of OCCCs were identified using a multi-Fisher's exact test.
Results: Hierarchical cluster analysis revealed two distinct clusters of OCCCs with different clinical outcomes. Patients from cluster-1 had a significantly shorter median progression-free survival (PFS) than those from cluster-2 (11 vs. 65 months, P = 0.009), although estimates for ovarian cancer-specific survival (OCS) did not reach statistical significance (P = 0.065). In multivariate analysis, suboptimal debulking surgery and genomic cluster were independently prognostic for PFS. Recurrently amplified genomic regions with a significantly higher prevalence in cluster-1 than cluster-2 OCCCs were identified and validated. HER2 gene amplification and protein overexpression was observed in 14% of OCCCs, suggesting that this may constitute a potential therapeutic target for a subgroup of these tumors.
Conclusions: OCCCs constitute a heterogeneous disease at the genomic level despite having similar histological features. The pattern of genomic aberrations in subgroups of OCCCs is of clinical significance. We have identified recurrently amplified regions that may harbor potential therapeutic targets for subgroups of OCCCs.
©2011 AACR.
Similar articles
-
Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.EBioMedicine. 2019 Dec;50:203-210. doi: 10.1016/j.ebiom.2019.11.017. Epub 2019 Nov 21. EBioMedicine. 2019. PMID: 31761620 Free PMC article.
-
Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progression.BMC Cancer. 2023 Jul 3;23(1):613. doi: 10.1186/s12885-023-11095-8. BMC Cancer. 2023. PMID: 37400764 Free PMC article.
-
Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.Cancer. 2012 Jun 1;118(11):2846-57. doi: 10.1002/cncr.26598. Epub 2011 Dec 2. Cancer. 2012. PMID: 22139760
-
Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy.Anticancer Res. 2023 Aug;43(8):3401-3410. doi: 10.21873/anticanres.16515. Anticancer Res. 2023. PMID: 37500149 Review.
-
Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma.Antioxidants (Basel). 2021 Jan 28;10(2):187. doi: 10.3390/antiox10020187. Antioxidants (Basel). 2021. PMID: 33525614 Free PMC article. Review.
Cited by
-
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.J Gynecol Oncol. 2016 May;27(3):e31. doi: 10.3802/jgo.2016.27.e31. J Gynecol Oncol. 2016. PMID: 27029752 Free PMC article. Review.
-
HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma.Virchows Arch. 2023 Oct;483(4):497-507. doi: 10.1007/s00428-023-03640-4. Epub 2023 Sep 7. Virchows Arch. 2023. PMID: 37676270
-
Bioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line.PLoS One. 2014 May 23;9(5):e98479. doi: 10.1371/journal.pone.0098479. eCollection 2014. PLoS One. 2014. PMID: 24858344 Free PMC article.
-
Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.Cancers (Basel). 2021 Aug 4;13(16):3939. doi: 10.3390/cancers13163939. Cancers (Basel). 2021. PMID: 34439094 Free PMC article.
-
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.Br J Cancer. 2013 Apr 30;108(8):1553-9. doi: 10.1038/bjc.2013.126. Epub 2013 Apr 4. Br J Cancer. 2013. PMID: 23558892 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous